Literature DB >> 25639238

Evidence gaps in the management of sickle cell disease: A summary of needed research.

William J Savage1, George R Buchanan, Barbara P Yawn, Araba N Afenyi-Annan, Samir K Ballas, Jonathan C Goldsmith, Kathryn L Hassell, Andra H James, Joylene John-Sowah, Lanetta Jordan, Richard Lottenberg, M Hassan Murad, Eduardo Ortiz, Paula J Tanabe, Russell E Ware, Sophie M Lanzkron.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25639238     DOI: 10.1002/ajh.23945

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  9 in total

1.  Red cell exchange transfusions lower cerebral blood flow and oxygen extraction fraction in pediatric sickle cell anemia.

Authors:  Kristin P Guilliams; Melanie E Fields; Dustin K Ragan; Cihat Eldeniz; Michael M Binkley; Yasheng Chen; Liam S Comiskey; Allan Doctor; Monica L Hulbert; Joshua S Shimony; Katie D Vo; Robert C McKinstry; Hongyu An; Jin-Moo Lee; Andria L Ford
Journal:  Blood       Date:  2017-12-18       Impact factor: 22.113

2.  Symptomatic Avascular Necrosis: An Understudied Risk Factor for Acute Care Utilization by Patients with SCD.

Authors:  Tiffany Yu; Timothy Campbell; Isabella Ciuffetelli; Carlton Haywood; Christopher Patrick Carroll; Linda Resar; John J Strouse; Sophie Lanzkron
Journal:  South Med J       Date:  2016-09       Impact factor: 0.954

3.  2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations.

Authors:  M Hassan Murad; Robert I Liem; Eddy S Lang; Elie A Akl; Joerg J Meerpohl; Michael R DeBaun; John F Tisdale; Amanda M Brandow; Sophie M Lanzkron; Stella T Chou; Starr Webb; Reem A Mustafa
Journal:  Blood Adv       Date:  2019-12-10

Review 4.  How I treat the older adult with sickle cell disease.

Authors:  Swee Lay Thein; Jo Howard
Journal:  Blood       Date:  2018-09-11       Impact factor: 22.113

5.  Trial design of comparing patient-specific versus weight-based protocols to treat vaso-occlusive episodes in sickle cell disease (COMPARE-VOE).

Authors:  Stephanie O Ibemere; Sarah B Dubbs; Huiman X Barnhart; Jacqueline L Brown; Caroline E Freiermuth; Patricia Kavanagh; Judith A Paice; John J Strouse; R Gentry Wilkerson; Paula Tanabe
Journal:  Contemp Clin Trials       Date:  2020-12-28       Impact factor: 2.226

6.  World Sickle Cell Day 2016 : A time for appraisal.

Authors:  Mya S Thein; Swee L Thein
Journal:  Indian J Med Res       Date:  2016-06       Impact factor: 2.375

Review 7.  Hydroxycarbamine: from an Old Drug Used in Malignant Hemopathies to a Current Standard in Sickle Cell Disease.

Authors:  Giovanna Cannas; Solène Poutrel; Xavier Thomas
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-02-15       Impact factor: 2.576

8.  A non-injected opioid analgesia protocol for acute pain crisis in adolescents and adults with sickle cell disease.

Authors:  Paul Telfer; Jonathan Bestwick; James Elander; Arlene Osias; Nosheen Khalid; Imogen Skene; Ruben Nzouakou; Joanne Challands; Filipa Barroso; Banu Kaya
Journal:  Br J Pain       Date:  2021-08-02

9.  Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion.

Authors:  Marcus A Carden; Meredith E Fay; Xinran Lu; Robert G Mannino; Yumiko Sakurai; Jordan C Ciciliano; Caroline E Hansen; Satheesh Chonat; Clinton H Joiner; David K Wood; Wilbur A Lam
Journal:  Blood       Date:  2017-10-04       Impact factor: 25.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.